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Paediatrics, Chang Gung Memorial Hospital, Taoyuan, TaiwanAbstractWe investigated the clinical and molecular characteristics of Candida albicans bloodstream infection (BSI) in children from a tertiary-level
medical centre in Taiwan over a 9-year period from January 2003 to December 2011. We performed multilocus sequence typing (MLST)
to investigate the genetic relatedness of these C. albicans BSI isolates. A total of 79 episodes of C. albicans BSI in 76 paediatric patients
were identiﬁed, including 41 (51.9%) from the paediatric intensive care unit, 24 (30.4%) from the neonatal intensive care unit and 14
(17.7%) from general wards. More than half (59.5%) of these patients had underlying chronic co-morbidities, and the majority (94.9%)
had a catheter or some other artiﬁcial device. All the isolates were susceptible to the antifungal agents tested. Only 32.9% (26/79)
received effective antifungal agents within 24 h of onset of candidaemia. Twenty-ﬁve (31.6%) patients had persistent candidaemia (>3 days
after the start of antifungal treatment) and candidaemia-attributable mortality rate was 22.8% (18/79). The 72 isolates available for MLST
yielded 53 unique diploid sequence types (DSTs). Forty-ﬁve DSTs were singletons and eight DSTs were shared by 27 (37.5%) isolates.
Seventy-one (98.6%) isolates were clustered within previously known clades. Based on the deﬁnition of two or more strains with shared
DST occurring within a period of 90 days, 10.1% of the infections were categorized as nosocomial clusters, most commonly identiﬁed in
the intensive care units. Although cluster-associated candidaemia was not associated with a higher mortality rate, none of the clusters
were identiﬁed by the hospital infection control team.
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p://dx.doi.org/10.1016/j.cmi.2015.06.024IntroductionCandida species are opportunistic pathogens that can cause
nosocomial infections in immunocompromised patients. The
mortality rate attributable to invasive candidiasis ranges from
19.3% to 40% [1–3]. Candidaemia has emerged as an important
infection control issue [3,4], because it contributes signiﬁcantly
to morbidity, and increases length of hospital stay and medical
costs [5–7]. In children, bloodstream infections (BSIs) causedious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Tsai et al. MLST analysis of Candida albicans 1018.e2by Candida mainly occur in paediatric and neonatal intensive
care units (PICUs and NICUs, respectively) or in patients with
underlying haematological/oncological malignancies, with
Candida albicans being the most common cause of Candida in-
fections [8–10]. Risk factors for children with candidaemia
include intravenous catheter placement with parenteral nutri-
tion, abdominal surgery, steroid usage and exposure to broad-
spectrum antibiotics [11–15].
Although C. albicans is less likely to have antifungal resis-
tance when compared with non-albicans Candida spp. [15,16],
it has a comparable mortality rate [2] and is occasionally
associated with clusters of nosocomial infection [17,18].
Identiﬁcation of relatedness between Candida species by using
molecular techniques with high discriminatory power is
essential for setting up infection control measures to reduce
nosocomial candidiasis [19,20]. However, information focused
on C. albicans BSIs in children, particularly regarding the
clinical data and molecular epidemiology, is limited. The
recently developed multilocus sequence typing (MLST)
method for C. albicans has proved to be a highly discriminatory
tool for molecular epidemiology [21]. In this study, we aimed
to characterize the clinical features and performed MLST to
analyse the genetic relatedness among paediatric BSI isolates
of C. albicans from a teaching hospital in Taiwan over a 9-year
period.Materials and methodsSetting and patient population
This study was conducted in the paediatric department of
Chang Gung Memorial Hospital (CGMH), a tertiary-level uni-
versity-afﬁliated hospital in northern Taiwan. The paediatric
department of CGMH is in a separate, 12-storey building with
four NICUs, two PICUs, and seven general wards. One of them
is specialized as a paediatric haematology/oncology division
(sixth ﬂoor), and there is a paediatric stem cell/bone marrow
transplantation unit. The total capacity of the paediatric
department of CGMH is 353 beds. All paediatric and neonatal
patients with BSIs caused by C. albicans that occurred between
January 2003 and December 2011 were enrolled in this study.
Except for multiple hospitalizations, each case patient was
included in the study only once, at the time of the ﬁrst positive
blood culture for C. albicans. During the study period, no
nosocomial clusters of candidaemia were reported by the
hospital infection control team in any of the wards or ICUs in
CGMH. This study was approved by the institutional review
board of CGMH, with a waiver of informed consent because all
the patient records and information were anonymized and de-
identiﬁed before analysis.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeData collection and deﬁnitions
The clinical information was from review of medical charts and
included age, sex, the length of the hospital stay before candi-
daemia, underlying diseases, history of immunosuppressive
therapy, exposure to antimicrobial agents, and surgery within
the previous 30 days, underlying diseases, neutropenia and the
presence of an intravenous catheter or any other artiﬁcial de-
vice at the time of candidaemia. The clinical manifestations at
the time of blood culture collection, ICU admission and the
antimicrobial regimens used were also collected.
An episode of C. albicans candidaemia was deﬁned as at least
one blood culture positive for C. albicans obtained from patients
with compatible clinical signs or symptoms [22]. The empirical
therapy was considered to be appropriate if an active antimi-
crobial agent in vitro was administered at the usual recom-
mended doses within the ﬁrst 24 h of blood culture obtained.
Persistent candidaemia was deﬁned as repeated positive blood
cultures for C. albicans for more than 3 days of antifungal agents.
Candidaemia-attributable mortality was deﬁned as patients who
died within 7 days after onset of candidaemia or in the presence
of persistent clinical sepsis or persistent candidaemia, or those
who died of candidaemia-associated complications [23,24].
Breakthrough candidaemia was deﬁned as new occurrence of
candidaemia while the patient was on antifungal prophylaxis
[25]. To evaluate the proportion of infections caused by clus-
tered isolates, a nosocomial cluster was deﬁned as identiﬁcation
of genetically closely related isolates from two or more patients
within a period of 90 days.
Candida albicans BSI isolate collection and MLST
analysis
In the Department of Paediatrics of CGMH, a fungus culture
was obtained from a peripheral blood vessel, or through central
venous access in the PICU when patients had clinical symptoms/
signs of sepsis and clinical fungaemia was suspected by the
attending physicians. The identiﬁcation of isolates to species
level was based on colony morphology on CHROMagar
Candida (BBL, Becton Dickinson, Sparks, MD) at 35°C,
microscopic morphology on cornmeal-Tween 80 agar, and a
commercially available biochemical identiﬁcation system (API
20C (bioMérieux, Marcy L’Etoile, France) or the Vitek 2 system
Vitek 2 ID-YST (bioMérieux)). All the C. albicans BSI isolates
were submitted to genotyping.
Multilocus sequence typing for C. albicans was performed
according to the method developed by Bougnoux et al. [26,27],
which was based on the variations of seven housekeeping gene
loci, including AAT1a, ACC1, VPS13, MPIb, ADP1, ZWF1b and
SYA1. The internal regions of these genes were ampliﬁed by
PCR and sequenced. Each allele’s nucleotide sequence was
assigned an allele number on the MLST website (http://ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e1–1018.e8
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allele numbers deﬁned a unique diploid sequence type (DST),
which represents its genotype. A dendrogram was constructed
with the use of Un-weighted Pair Group Method with Arith-
metic mean (UPGMA) by Molecular Evolutionary Genetics
Analysis version 6.0 (MEGA6). The numbered clades of
C. albicans were described as previously [28]. Numbers at nodal
points indicate bootstrap values (%) for 1000 replications.
Putative relatedness between isolates was determined by
eBURST (http://eburst.mlst.net/). The eBURST algorithm was
used for not only placing all related isolates into clonal com-
plexes but also for predicting the ancestral DST of each com-
plex. The results of eBURST displayed the most parsimonious
patterns of each descent from the ancestral DST type.
Antifungal susceptibility testing
Susceptibility of the C. albicans BSI isolates to nine antifungal
agents was determined by a broth microdilution method using
a Sensititre YeastOne system (Trek Diagnostic Systems Ltd.,
East Grinstead, UK) according to the manufacturer’s in-
structions [29,30]. The MIC was recorded as the highest
concentration of antifungal agent resulting in the development
of a blue colour. All Sensititre® plates include positive control
wells, and Candida krusei* ATCC® 6258 and Candida parapsilosis
ATCC® 22019 were used as the quality control strains. Flu-
conazole, itraconazole, voriconazole, posaconazole, micafungin,
caspofungin, anidulafungin, 5-ﬂucytosine and amphotericin B
were prepared according to the CLSI methods. The criteria for
susceptibility of C. albicans BSI isolates to nine antifungal agents
were based on MIC breakpoints of Candida spp. recommended
by the CLSI [31].
Statistical analysis
For clinical characteristics, we described the differences be-
tween non-neonatal candidaemia in children and neonatal
candidaemia. Statistical signiﬁcance for unadjusted comparisons
was determined by the chi-squared or Fisher exact test for
categorical data, and Student’s t test or the Wilcoxon/Mann–
Whitney test for continuous variables. Tests were two-sided
and a p value < 0.05 was considered signiﬁcant. All statistics
were performed using the commercially available software SPSS
16.0 for Windows (SPSS®, Chicago, IL, USA).ResultsClinical characteristics of C. albicans BSIs
During the study period, a total of 79 episodes of C. albicans BSI
in 76 patients were identiﬁed (three patients had two episodes
of C. albicans BSI in two hospitalizations), including 24 (30.4%)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfrom NICUs, 41 (51.9%) from PICUs and 14 (17.7%) from
general wards. Table 1 lists the demographics, clinical mani-
festations and outcomes for all patients with C. albicans BSIs.
Paediatric and neonatal patients had a length of hospital stay
before C. albicans BSI with a median (interquartile range) of 26.5
(14.5–47.0) and 23.0 (14.5–45.5) days, respectively. However,
there were two episodes of early-onset sepsis within 3 days of
life in the NICU.
More than half of the case patients had underlying chronic
disorders (47/79, 59.5%) (Table 1). About 40% (27 children, ﬁve
neonatal patients) had multiple chronic conditions. Almost all
the patients had previous exposure to antibiotics (94.9%) or a
catheter or artiﬁcial device (94.9%). The majority of patients
had total parenteral nutrition and/or intrafat infusion (69.6%) at
onset of candidaemia, but very few cases had neutropenia
(6.3%) or recent immunosuppressive therapy (7.6%) at onset of
candidaemia.
Although all C. albicans BSI isolates were susceptible to all
antifungal agents tested, only 32.9% (26/79) received effective
antifungal agents within 24 h of onset of candidaemia. There
were four episodes of breakthrough candidaemia for patients
with antifungal prophylaxis, and 31.6% (25 episodes) had
persistent candidaemia even after effective antifungal therapy.
The most common antifungal agents used were ﬂuconazole
(70.8% for neonates and 65.5% for children) and amphotericin-
B (29.2% and 30.9%, respectively). One patient had fulminant
sepsis and died before any antifungal agent was prescribed.
With antifungal therapy, 43 (54.4%) episodes responded well
and all symptoms and signs resolved within 3 days; ten (12.7%)
resolved at 3–7 days; and 36.7% had modiﬁcation of antifungal
therapy. A total of 26 (34.2%) patients died in the hospital,
including six early deaths within 3 days of candidaemia and 12
deaths with progressive multi-organ failure after candidaemia.
The candidaemia-attributable mortality rate was 22.8% (18/79).
Antifungal susceptibility testing
The MIC distributions and in vitro susceptibilities of 73
C. albicans isolates are summarized in Table 2. In terms of MIC90
values (MIC required to inhibit 90% of the isolates), micafungin
and voriconazole had the lowest level of 0.008 mg/L. All isolates
had an MIC of 1 mg/L to all antimicrobial agents and were
considered susceptible according to the CLSI breakpoints [31].
Molecular epidemiology
A total of 72 C. albicans BSI isolates from 71 patients were
available for MLST analysis, and 53 DSTs were identiﬁed.
Twenty-six isolates (36.1%) belonged to 26 novel DSTs ﬁrst
identiﬁed (Table 3). Of these 53 DSTs, 45 (62.5%) were sin-
gletons, and eight were shared by 27 (37.5%) isolates. DST693
and DST1849 were the two major types with seven and ﬁveious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e1–1018.e8
TABLE 1. The clinical characteristics of 79 episodes of Candida albicans bloodstream infections in 76 paediatric patients
Characteristics
PICU
(total n [ 41)
NICU
(total n [ 24)
General wards
(total n [ 14)
Age (years for PICU and wards, and days for NICU), median (IQR) 4.0 (0.8–7.3) 21.5 (15.0–54.0) 4.0 (1.0–13.0)
Gender (male/female) 20 (48.8)/21 (51.2) 12 (50)/12 (50) 7 (50)/7 (50)
Length of hospital stay before candidaemia (days), median (IQR) 29.0 (15.5-53.0) 23.0 (14.5–45.5) 24.0 (13.0–41.0)
Underlying chronic conditionsa
Haematological/Oncological malignancy 2 (4.9) 0 (0) 4 (28.6)
Cardiopulmonary disorder 6 (14.6) 3 (12.5) 0 (0)
Neurological disorder, congenital or acquired 15 (36.6) 2 (8.3) 2 (14.3)
Gastrointestinal disorder 16 (39.0) 5 (20.8) 6 (42.9)
Metabolic 8 (19.5) 1 (4.2) 2 (14.3)
Congenital anomalies 3 (7.3) 0 (0) 1 (7.1)
Neutropenia 3 (7.3) 0 (0) 2 (14.3)
Previous antibiotics exposureb 38 (92.7) 23 (95.8) 14 (100)
Previous bacteraemiab 7 (17.1) 7 (29.2) 6 (42.9)
Use of immunosuppressive agentsb 3 (7.3) 0 (0) 3 (21.4)
Under antifungal prophylaxis 2 (4.9) 0 (0) 2 (14.3)
Surgeryb 9 (22.0) 4 (16.7) 2 (14.3)
Intravascular catheterization 33 (80.5) 22 (91.7) 11 (78.6)
Artiﬁcial devices other than intravascular catheterization 13 (31.7) 14 (58.3) 6 (42.9)
Use of total parenteral nutrition and/or intrafat 26 (63.4) 20 (83.3) 9 (64.3)
Clinical manifestations
Severe sepsis and/or septic shock 13 (31.7) 4 (16.7) 2 (14.3)
Disseminated intravascular coagulopathy 7 (17.1) 3 (12.5) 1 (7.1)
Breakthrough candidaemia/persistent candidaemia 2 (4.9)/15 (36.6) 0 (0)/6 (25.0) 2 (14.3)/4 (28.6)
Treatment and outcomes
Appropriate empirical antifungal therapy within 24 hours 10 (24.4) 8 (33.3) 8 (57.1)
Duration of candidaemia (days), median (IQR)c 1.0 (1.0-6.0) 1.0 (1.0-3.0) 1.0 (1.0-4.0)
Complete response within 72 h 22 (53.7) 14 (58.3) 7 (50.0)
Complete response at 3–7 days after antifungal treatment 4 (9.8) 3 (12.5) 3 (21.4)
Candidaemia-attributable mortality 8 (19.5) 6 (25.0) 4 (28.6)
In-hospital mortality 12/38 (31.6) 8/24 (33.3) 6/14 (42.9)
All data were expressed as number (percentage, %), unless indicated otherwise.
IQR, interquartile range; NICU, neonatal intensive care unit; PICU, paediatric intensive care unit.
aIndicating the presence at onset of candidaemia; some patients had more than one underlying chronic condition or co-morbidity.
bWithin 30 days before onset of candidaemia.
cAfter appropriate antifungal treatment.
CMI Tsai et al. MLST analysis of Candida albicans 1018.e4isolates, respectively (Table 3). To assign these isolates to
existing clades, we performed an analysis of these isolates
together with 996 DSTs (from ST1 to ST999) retrieved from
the MLST database (57.8% of all DSTs currently available in the
MLST database: http://calbicans.mlst.net). Of these 72 BSI iso-
lates, 71 (98.6%) isolates clustered within previously recognized
clades (clades 1 to 18), but one (P054) (1.4%) was a singlet
[19,26]. Clade 1 (22.2%) constituted the greatest proportion of
the isolates, followed by clade 4 (13.9%) and clade 3 (9.7%).
Table 3 presents the clade distribution of the 72 isolatesTABLE 2. MIC distribution of 73 Candida albicans bloodstream isol
No. of isolates with MIC (mg/L) of:
£0.004 0.008 0.015 0.03 0.06 0.12
Candida albicans (total n = 73 tested)
5-Flucytosine 55 7
Amphotericin B
Fluconazole 5
Itraconazole 15 38 20
Posaconazole 14 51 8
Voriconazole 72 1
Micafungin 72 1
Caspofungin 1 3 13 54 3
Anidulafungin 14 13 40 6
MIC50 and MIC90, MIC required to inhibit 50% and 90% of the isolates, respectively.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infestratiﬁed by the wards in CGMH over the study period. Within
individual wards, one to 13 different clades were identiﬁed.
Fig. 1 shows the phylogenetic relatedness between 72
C. albicans BSI isolates from the paediatric department of
CGMH and 996 strains retrieved from the MLST database. The
72 isolates were distributed over all clades, except clades 2 and
13, which were geographically clustered in Europe and Africa
[26]. The UPGMA clades 1, 4 and 11 were most consistent
during the rapid expansion of the database. The CGMH isolates
were distributed unevenly, especially in clades 3, 4 and 11ates from paediatric patients
MIC (mg/L)
0.25 0.5 1 2 Range MIC50 MIC90
3 4 4 0.06–1 0.06 0.5
7 66 0.25–0.5 0.5 0.5
29 38 1 0.12–1 0.5 0.5
0.015–0.06 0.03 0.06
0.008–0.03 0.15 0.03
0.008–0.015 0.008 0.008
0.008–0.015 0.008 0.008
0.008–0.12 0.06 0.06
0.015–0.12 0.06 0.06
ctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e1–1018.e8
TABLE 3. Multilocus sequence typing of 72 Candida albicans isolates collected from paediatric patients stratiﬁed by wards
Clade
No. (%) of
isolates
PICU (total n[ 39)
NICU (total
n [ 19) Ward (total n [ 14)
Major DST DST (n)a2L1 2L2 Surgical 3L1 3L2 5L 6L 7L 8L 9L 10L 11L
1 16 (22.2) 4 3 1 3 1 2 0 0 2 0 0 0 1849 1082, 1097, 1849 (5), 2427*, 2513*, 2516*, 2519*, 2521*,
2522*, 2524*, 2527*, 2528*
3 7 (9.7) 2 1 0 1 0 1 1 0 0 1 0 0 693 693 (7)
4 10 (13.9) 3 0 2 4 0 0 0 0 0 1 0 0 659 659 (3), 1068, 1069, 1612, 1613, 1977, 2520*, 2524*
5 3 (4.2) 0 2 0 0 1 0 0 0 0 0 0 0 — 2511*, 2514*, 2534*
6 3 (4.2) 1 0 1 1 0 0 0 0 0 0 0 0 — 1889, 2515*,2525*
7 1 (1.4) 0 0 1 0 0 0 0 0 0 0 0 0 — 811
8 5 (6.9) 3 1 0 0 0 0 0 0 0 0 1 0 365 365 (3), 1895, 2533*
9 4 (5.6) 1 2 0 0 0 1 0 0 0 0 0 0 — 1371, 2518*, 2526*, 2530*
10 1 (1.4) 1 0 0 0 0 0 0 0 0 0 0 0 — 609
11 3 (4.2) 2 0 0 0 0 1 0 0 0 0 0 0 — 461, 569, 1751
12 3 (4.2) 1 0 0 1 0 0 1 0 0 0 0 0 — 601, 719, 1752
14 1 (1.4) 1 0 0 0 0 0 0 0 0 0 0 0 — 2517*
15 1 (1.4) 0 0 0 0 1 0 0 0 0 0 0 0 — 2532*
16 5 (6.9) 1 1 0 0 0 0 1 0 0 1 1 0 669, 1757 669 (2), 1723, 1757 (2)
17 4 (5.6) 1 0 1 0 0 0 1 1 0 0 0 0 443 443 (3), 2531*
18 4 (5.6) 1 1 0 0 0 0 0 0 0 1 0 1 732 732 (2), 2512*, 2523*
Singlet 1 (1.4) 0 0 0 1 0 0 0 0 0 0 0 0 — 2529*
Total 72 (100) 22 11 6 11 3 5 4 1 2 4 2 1
DST, diploid sequence type; PICU, paediatric intensive care unit; NICU, neonatal intensive care unit.
aThe DST numbers marked by an asterisk were newly assigned from this study.
FIG. 1. The radial distribution of Candida albicans isolates from paediatric wards in the Chang Gung Memorial Hospital (CGMH) and reference strains.
The allelic concatenated nucleic acid sequences of 72 CGMH isolates and 996 reference strains retrieved from a multilocus sequence typing database
were phylogenetically analysed by UPGMA. The noted clade numbers are assigned according to reference [25]. Two clades (2 and 13) in italic letters
contain no CGMH isolates. All open circles represent CGMH isolates. The scale bar indicates the p-distance.
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CMI Tsai et al. MLST analysis of Candida albicans 1018.e6(Fig. 1), which suggested close genetic relatedness of CGMH
isolates within the same clades.
Eight (10.1%) isolates were categorized into four clusters
(Table 4) by our deﬁnition. The majority of clustered isolates
(seven isolates, 87.5%) were identiﬁed from the patients in
PICUs or NICUs. In addition, one patient had two episodes of
candidaemia caused by an indistinguishable strain during two
hospitalizations. Neither the speciﬁc DST nor cluster-
associated candidaemia was correlated with treatment out-
comes or patient origin. The candidaemia-attributable mortality
rate and case-fatality rates for cluster-associated cases did not
differ statistically signiﬁcantly from those of sporadic nosoco-
mial infections.DiscussionIn addition to the clinical characteristics of C. albicans BSIs in
children, this study aimed to contribute to a long-term genetic
database of C. albicans BSI isolates of Taiwanese children for
global epidemiology [32,33] and investigate whether different
characteristics can be attributed to certain speciﬁc molecular
types in our hospital. In the present study, we did not identify
any speciﬁc molecular type that could be strongly correlated
with certain patient characteristics, drug resistance, or treat-
ment outcomes. However, results from the present study
showed that C. albicans potentially accounted for small out-
breaks inside the hospital and these escaped identiﬁcation by
the hospital infection control team.
In contrast to adult patients who have cancer or an immu-
nocompromised status that places them at high risk for devel-
oping candidaemia [34,35], the majority of underlying chronic
conditions in paediatric patients in this study were neurological
and gastrointestinal co-morbidities. It is noticeable that the
children with C. albicans BSIs in the present study almost all had
previous antibiotic exposure, long-term hospitalization, or a
catheter or artiﬁcial device in place. These ﬁndings are consistent
with those previously reported, in which retained intravascularTABLE 4. Clustered episodes of genetically related Candida
albicans candidaemia
Clade DST Ward/location Isolation date (month/day/year)
1 1849 2LPICU 1/25/2006
3LNICU 1 2/15/2006
3 693 2LPICU 10/11/2009
2LPICU/9La 12/11/2009
3 693 3LNICU 1 12/4/2010
5LNICU 1 12/31/2010
8 365 2LPICU 7/24/2006
2LPICU 7/31/2006
PICU, paediatric intensive care unit; NICU, neonatal intensive care unit.
aAlthough the isolate was obtained when the patient was in the general ward, he
had been in the PICU for a long time.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecatheters, intestinal failure, presence of gastrostomy tube, and/or
receipt of total parenteral nutrition were identiﬁed as indepen-
dent risk factors of candidaemia [5,8,11,12,36].
Clinical manifestations of candidaemia in paediatric patients
are non-speciﬁc, like clinical sepsis, so empiric antifungal agents
were administered to only one-third of the patients within 24 h
of the onset of candidaemia in this cohort. Although all
C. albicans isolates were susceptible to all antifungal agents
tested in this study, only 54.4% of the patients had a good
response within 3 days after initiating antifungal therapy,
whereas nearly one-third had persistent candidaemia and the
attributable mortality rate was up to 22.8%. The relatively high
case-fatality rate may be partly explained by the high percentage
of underlying chronic conditions in our cohort, which was
consistent with previous studies [1,2,7,37]. All of these ﬁndings
highlight the necessity for infection control measures to avoid
the occurrence of candidaemia and a better treatment strategy
to reduce mortality and morbidity in these patients.
There are several molecular typing methods to investigate
C. albicans clones [38]. In addition to MLST, the methods include
PCR ﬁngerprinting and random ampliﬁcation of polymorphic
DNA [39], restriction fragment length polymorphism analysis
[40], pulsed-ﬁeld gel electrophoresis [19], and Southern blot
hybridization with discriminating probes [38]. The strengths of
MLST are not only that it is a highly discriminative tool for ana-
lysing genetic relatedness among sequential isolates from the
same or different study sites, but also that it allows inter-
laboratory comparisons worldwide. However, MLST may have
some limitations in typing isolates from different patients,
because some studies have shown different pulsed-ﬁeld gel
electrophoresis or ﬁngerprinting patterns in shared DST isolates
[19,20,41]. Although MLST has been found to be superior to
pulsed-ﬁeld gel electrophoresis and at least comparable to
Southern hybridization [42,43], a strict deﬁnition of a nosoco-
mial cluster as those occurring within a period of 90 days [18]
would make the cluster identiﬁcation more effective and reliable.
Compared with recent studies [19,20,41,44,45], the two most
predominant clades (clade 1 and 4) for the isolates in this cohort
were identiﬁed mainly in Asian countries. Interestingly, all seven
CGMH isolates that clustered in clade 3 belonged to DST 693,
whichwas ﬁrst identiﬁed from the sputumof a patientwith AIDS in
1996 in Taiwan [41] and which belongs to the global clonal com-
plex 20 by eBURST analysis. These suggest that DST 693 might
have some advantage to ﬁt the niche in the hospital of northern
Taiwan. In addition, although some studies indicated that clonal
strains accounted for themajority ofmortality cases [42], our data,
consistent with most studies [19,20,43,45,46], showed no signiﬁ-
cant associations between clusters and clinical characteristics.
Although most studies collected C. albicans BSI isolates from
several hospitals and suggested that interhospital strainctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1018.e1–1018.e8
1018.e7 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMItransmission was unlikely, even though some of their BSI isolates
had identical DSTs [19,42], our study focused on strains within
the same hospital and found nosocomial clusters accounted for
10.1% of total. Therefore, horizontal transmission of C. albicans
between different wards, as well as within the unit, was possible
[20,46]. A recent national multicentre study from Iceland
showed as many as 23% of all cases of C. albicans BSIs were
attributable to nosocomial clusters [18], but it was limited by the
lower discriminatory method of randomly ampliﬁed poly-
morphic DNA analysis. There have been several studies that
demonstrated single strains responsible for some outbreaks of
candidaemia in the same hospital, and some of them lasted for a
long period of time, sometimes for years [47,48].
There were some limitations in this study. This study was
from a single centre and the results may be less generalizable
than those from multicentre studies. Besides, not all isolates
from the reported episodes were available for genotyping.
Owing to the relatively small numbers in this study cohort,
there would be an inadequate statistical power to either
compare the differences between neonatal and paediatric
C. albicans BSIs or allow for any determination of associations
between molecular types and clinical data. Furthermore,
although MLST is well known for its high discriminatory power
and reproducibility, lack of the second method complementary
to MLST, when an identical DST was shared by more than one
isolate, may result in limitations in reﬂecting the real situation.
In conclusion, C. albicans constitutes an important cause of
nosocomial BSI in children and causes a signiﬁcant amount of
mortality and morbidity, especially in those with underlying
chronic co-morbidity. MLST is highly discriminating among
C. albicans isolates. Although the possibly horizontal trans-
mission and clustered nosocomial infections accounted for only
a small percentage of candiaemia, further active surveillance
network is warranted for better understanding of the molecular
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